Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Heart failure and statins--why do we need a clinical trial?

Literature DB >> 15803258

Heart failure and statins--why do we need a clinical trial?

M Böhm¹, A Hjalmarson, J Kjekshus, U Laufs, J McMurray, D J van Veldhuisen.

Abstract

The effect of statins to reduce mortality and morbidity in primary and secondary prevention as well as in acute coronary syndrome is well established. Recent data show that pleiotropic effects might also have direct effects on the myocardial cell. However, in chronic heart failure the outcome is inversely related to LDL-plasma concentrations and other pleiotropic effects might impair mitochondrial function. Since there are no safety data on the use of statins in chronic heart failure, a controlled randomized and placebo-controlled trial is urgently needed.

Entities: Disease

Mesh：

Substances：

Year: 2005 PMID： 15803258 DOI： 10.1007/s00392-005-0210-9

Source DB: PubMed Journal: Z Kardiol ISSN： 0300-5860

64 in total

1. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors: P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal: N Engl J Med Date: 2001-06-28 Impact factor: 91.245

Review 2. Regulation of the mevalonate pathway.

Authors: J L Goldstein; M S Brown
Journal: Nature Date: 1990-02-01 Impact factor: 49.962

3. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.

Authors: M Takemoto; K Node; H Nakagami; Y Liao; M Grimm; Y Takemoto; M Kitakaze; J K Liao
Journal: J Clin Invest Date: 2001-11 Impact factor: 14.808

4. Endotoxin and immune activation in chronic heart failure: a prospective cohort study.

Authors: J Niebauer; H D Volk; M Kemp; M Dominguez; R R Schumann; M Rauchhaus; P A Poole-Wilson; A J Coats; S D Anker
Journal: Lancet Date: 1999-05-29 Impact factor: 79.321

5. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.

Authors: G O'Driscoll; D Green; R R Taylor
Journal: Circulation Date: 1997-03-04 Impact factor: 29.690

6. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.

Authors: J D Luo; W W Zhang; G P Zhang; J X Guan; X Chen
Journal: Clin Exp Pharmacol Physiol Date: 1999-11 Impact factor: 2.557

7. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure.

Authors: Y W Xie; W Shen; G Zhao; X Xu; M S Wolin; T H Hintze
Journal: Circ Res Date: 1996-09 Impact factor: 17.367

8. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors: J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal: N Engl J Med Date: 1995-11-16 Impact factor: 91.245

9. Selective impairment of vagally mediated, nitric oxide-dependent coronary vasodilation in conscious dogs after pacing-induced heart failure.

Authors: G Zhao; W Shen; X Xu; M Ochoa; R Bernstein; T H Hintze
Journal: Circulation Date: 1995-05-15 Impact factor: 29.690

Heart failure and statins--why do we need a clinical trial?

1. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Review 2. Regulation of the mevalonate pathway.

3. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.

4. Endotoxin and immune activation in chronic heart failure: a prospective cohort study.

5. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.

6. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.

7. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure.

8. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

9. Selective impairment of vagally mediated, nitric oxide-dependent coronary vasodilation in conscious dogs after pacing-induced heart failure.

10. Triglyceride-rich lipoproteins prevent septic death in rats.

Review 1. Hypertriglyceridemia-why, when and how should it be treated?

Review 2. HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.

Review 3. The case for statin therapy in chronic heart failure.

4. Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study.

5. Impact of adherence to statins on chronic heart failure in primary prevention.

Review 6. Statins in the treatment of chronic heart failure: a systematic review.

Review 7. A Review of the Role of Statins in Heart Failure Treatment.